Abstract
Approximately 22,000 cases of ovarian cancer occur each year in the United States, and likely fewer than 2000 cases of mucinous ovarian cancers. Although 90% of patients with mucinous ovarian cancer present with stage I disease and have curative surgeries, advanced-stage disease is known to have a poor response to standard platinum- and taxane-based chemotherapy. Despite limited enthusiasm, standard chemotherapy is still recommended for most patients with advanced-stage mucinous malignancies of the ovary. This report presents an unusual case of a woman with HER2-positive metastatic mucinous carcinoma of the ovary treated with chemotherapy regimens typically used for colorectal malignancies, followed by epidermal growth factor receptor-targeted therapies.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Biomarkers, Tumor / analysis*
-
Brain Neoplasms / radiotherapy
-
Brain Neoplasms / secondary
-
Brain Neoplasms / surgery
-
Cystadenocarcinoma, Mucinous / drug therapy*
-
Cystadenocarcinoma, Mucinous / pathology
-
Cystadenocarcinoma, Mucinous / secondary
-
ErbB Receptors / antagonists & inhibitors
-
Female
-
Humans
-
Lapatinib
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / metabolism
-
Ovarian Neoplasms / pathology
-
Quinazolines / therapeutic use
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-2 / metabolism
-
Trastuzumab
-
Vascular Endothelial Growth Factors / antagonists & inhibitors
-
Young Adult
Substances
-
Antibodies, Monoclonal, Humanized
-
Biomarkers, Tumor
-
Quinazolines
-
Vascular Endothelial Growth Factors
-
Lapatinib
-
Bevacizumab
-
EGFR protein, human
-
ERBB2 protein, human
-
ErbB Receptors
-
Receptor, ErbB-2
-
Trastuzumab